NewsStocksSELLAS Life Sciences (SLS) Stock Jumps 20% After Hours as Phase 3 REGAL Trial Nears Final Analysis

SELLAS Life Sciences (SLS) Stock Jumps 20% After Hours as Phase 3 REGAL Trial Nears Final Analysis

Author: Blockonomi·

Key Takeaways

  • •SLS shares rose 20% in after-hours trading Thursday after the Phase 3 REGAL trial's 80th event triggered its final analysis, with topline results expected in the fourth quarter.
  • •The REGAL study evaluates galinpepimut-S in acute myeloid leukemia patients in second complete remission, using overall survival as its primary endpoint.
  • •Third-quarter net loss widened to $10.1 million from $6.8 million a year earlier, but the per-share loss fell to $0.05 from $0.06 as the share count grew to about 202.4 million, and cash rose to $134.7 million from $71.8 million at the end of 2025.
  • •SELLAS has enrolled 40 of 80 planned patients in its Phase 2 trial of SLS009, known as tambiciclib, in newly diagnosed acute myeloid leukemia, with early data due in the fourth quarter.
  • •Earlier Phase 2 results showed SLS009 response rates of 54% in monocytic disease and 57% in TP53-mutated relapsed or refractory AML, with completed findings to be presented at the American Society of Hematology meeting in December.
SELLAS Life Sciences (SLS) Stock Jumps 20% After Hours as Phase 3 REGAL Trial Nears Final Analysis

SELLAS Life Sciences Group, Inc. (SLS) shares climbed 20% in after-hours trading on Thursday, rebounding from a 4.63% decline in the regular session. The move followed the company's indication that data from its pivotal leukemia trial is drawing near, after the Phase 3 REGAL study reached the milestone that sets its final analysis in motion. The stock remains up more than 100% so far in 2026.

REGAL Trial Enters Final Analysis Stage

The Phase 3 REGAL trial recorded its 80th event in October, triggering the final analysis process. Trials structured this way set their analysis clock by accumulated patient outcomes rather than a fixed date, which is why the milestone itself, not a calendar entry, starts the countdown to results. The study evaluates galinpepimut-S, known as GPS, in patients with acute myeloid leukemia who are in second complete remission. Overall survival is the trial's primary goal. For a company that has said it is preparing for a possible GPS filing, the final-analysis trigger is the step that turns accumulated trial data into results that can support a regulatory submission.

Next steps include database lock, unblinding and statistical analysis. Topline results are due in the fourth quarter, though the company had previously targeted November.

Chief Executive Officer Angelos Stergiou said the company continues to execute across both clinical programs, adding that important milestones are getting closer.

Why the Loss Per Share Got Smaller

SELLAS reported a third-quarter net loss of $10.1 million, or $0.05 per share, compared with a loss of $6.8 million, or $0.06 per share, a year earlier. Although the total loss grew, the per-share figure fell because the average share count jumped to roughly 202.4 million from 108.4 million. The per-share loss matched Wall Street's forecast, and revenue was zero, also in line with estimates.

Research and development costs rose to $7.0 million from $4.2 million, driven by higher manufacturing, consulting and trial expenses as the company prepares for a possible GPS filing. General and administrative costs increased to $4.3 million from $2.9 million. The operating loss totaled $11.3 million for the quarter and $31.2 million for the first nine months.

Cash and equivalents stood at $134.7 million as of September 30, up from $71.8 million at the end of 2025, a larger reserve at a stage when trial-related spending is climbing toward a potential filing.

SLS009 and the December Calendar

SELLAS is also testing SLS009, known as tambiciclib, in newly diagnosed acute myeloid leukemia. Forty of the 80 planned patients have been enrolled in that Phase 2 study.

Earlier Phase 2 work in relapsed or refractory acute myeloid leukemia showed response rates of 54% in monocytic disease and 57% in TP53-mutated disease, with median overall survival of 5.8 months and 8.8 months, respectively. The company said those figures compare with historical outcomes of about 2.5 months, while noting that such comparisons do not prove superiority in a randomized trial.

Preclinical work in pancreatic cancer models also supports further study of SLS009 alongside RAS-directed therapy.

Early data from the newly diagnosed acute myeloid leukemia trial is due in the fourth quarter. The company will present the completed Phase 2 findings at the American Society of Hematology meeting in December, the hematology field's principal annual research forum. That places REGAL topline data, the first SLS009 readouts and a scientific showcase inside the same few weeks, creating a dense stretch of clinical checkpoints to close the year.